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MaBACKGROUND In LQTS, b-blocker therapy is effective in reducing the risk of cardiac events (syncope, aborted cardiac
arrest, sudden cardiac death). Limited studies have compared the efﬁcacy of different b-blockers.
OBJECTIVES The goal of this study was to compare the efﬁcacy of different b-blockers in long QT syndrome (LQTS)
and in genotype-positive patients with LQT1 and LQT2.
METHODS The study included 1,530 patients from the Rochester, New York–based LQTS Registry who were prescribed
common b-blockers (atenolol, metoprolol, propranolol, or nadolol). Time-dependent Cox regression analyses were used
to compare the efﬁcacy of different b-blockers with the risk of cardiac events in LQTS.
RESULTS Relative to being off b-blockers, the hazard ratios and 95% conﬁdence intervals (CIs) for ﬁrst cardiac events
for atenolol, metoprolol, propranolol, and nadolol were 0.71 (0.50 to 1.01), 0.70 (0.43 to 1.15) 0.65 (0.46 to 0.90), and
0.51 (0.35 to 0.74), respectively. In LQT1, the risk reduction for ﬁrst cardiac events was similar among the 4 b-blockers,
but in LQT2, nadolol provided the only signiﬁcant risk reduction (hazard ratio: 0.40 [0.16 to 0.98]). Among patients who
had a prior cardiac event while taking b-blockers, efﬁcacy for recurrent events differed by drug (p ¼ 0.004), and pro-
pranolol was the least effective compared with the other b-blockers.
CONCLUSIONS Although the 4 b-blockers are equally effective in reducing the risk of a ﬁrst cardiac event in LQTS,
their efﬁcacy differed by genotype; nadolol was the only b-blocker associated with a signiﬁcant risk reduction in patients
with LQT2. Patients experiencing cardiac events during b-blocker therapy are at high risk for subsequent cardiac events,
and propranolol is the least effective drug in this high-risk group. (J Am Coll Cardiol 2014;64:1352–8) © 2014 by the
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associated with serious cardiac events that include
syncopal episodes, aborted cardiac arrest, and sud-
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AB BR E V I A T I O N S
AND ACRONYM S
ICD = implantable
cardioverter-deﬁbrillator
LQTS = long QT syndrome
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1353LQTS genotypes (LQT1 and LQT2) (5). The aim of this
study was to compare the relative efﬁcacy among the
most commonly prescribed b-blockers in patients
with LQTS who were enrolled in the Rochester, New
York–based LQTS Registry.SEE PAGE 1359 QTc = QT interval
measurements corrected for
rateMETHODS
STUDY POPULATION. The study population was
drawn from the Rochester-based LQTS Registry and
involved patients who were prescribed b-blockers
before 40 years of age and did not have an implantable
cardioverter-deﬁbrillator (ICD) before initiation of b-
blocker therapy. LQTS was diagnosed by prolonged
QT interval criteria for age and sex, as previously re-
ported (6,7) or by the presence of a genetic LQTS
mutation (7). Those patients who simultaneously
received 2 different b-blockers during follow-up were
excluded. The study population involved 1,530 pa-
tients. The University of Rochester Medical Center
Research Subjects Review Board approved this study.
TIME ORIGIN AND FOLLOW-UP. We selected the time
origin as the next day after patients received their
ﬁrst b-blocker. Follow-up was censored when pa-
tients reached 40 years of age or had an ICD inserted,
whichever occurred ﬁrst. These censoring criteria
were chosen to minimize the confounding inﬂuence
of other cardiovascular diseases and device therapies
on LQTS-related cardiac events.
PRIMARY AND SECONDARY ENDPOINTS. The pri-
mary endpoint was the occurrence of the patient’s
ﬁrst cardiac event of any type (syncope, aborted car-
diac arrest, or sudden cardiac death) after b-blocker
initiation. The secondary endpoint was restricted to
the more serious occurrence of ﬁrst aborted cardiac
arrest or sudden cardiac death, with syncope treated
as a time-dependent covariate. The term “ﬁrst cardiac
event” reﬂects the ﬁrst cardiac event happening after
starting b-blocker therapy, regardless of prior cardiac
event history.
RECURRENT CARDIAC EVENTS. In this analysis, the
time origin was deﬁned as the time when the ﬁrst
cardiac event occurred while taking b-blocker ther-
apy, with similar censoring criteria at 40 years of age
or at deﬁbrillator insertion during subsequent follow-
up. The term “recurrent cardiac event” reﬂects the
subsequent cardiac event in patients with 1 cardiac
event while taking b-blockers in reference to time
origin (b-blocker initiation).
STATISTICAL ANALYSIS. This study grouped pa-
tients who started taking b-blockers into 4 categoriesaccording to their ﬁrst b-blocker prescribed
(atenolol, metoprolol, propranolol, or nado-
lol). Baseline clinical characteristics were
compared by ﬁrst b-blocker type using the
Kruskal-Wallis test for continuous variables
and chi-square tests for categorical variables.
Continuous variables were summarized by
the mean  SD, and categorical variables
were summarized by frequencies and proportions.
Cox models were used to estimate the hazard ratio
for each of the 4 time-dependent effects of b-blockers
relative to patients who discontinued b-blockers
after therapy initiation (8). Time-dependent analyses
dynamically accounted for those patients who
switched or stopped b-blocker therapy. Cox models
were adjusted for age when b-blocker was started and
calendar time, starting with values at therapy initia-
tion and updating daily thereafter. Adjustment for
LQTS severity was also carried out by including the
following covariates: the history of cardiac events
before b-blocker initiation; and the baseline QT in-
terval measurements corrected for heart rate (QTc),
with additional time-dependent covariate for syn-
cope in the secondary endpoint analysis, that is, if
syncope occurred after b-blocker therapy initiation
but before the occurrence of the serious endpoint
(ﬁrst aborted cardiac arrest or sudden cardiac death).
The cumulative probability of a recurrent cardiac
event following the ﬁrst cardiac event was compared
by the type of b-blocker using the Kaplan-Meier
method with the log-rank test for signiﬁcance. Cox
regression was used to estimate the hazard ratio
adjusted for the same variables as in the primary
analysis, except for the history of prior cardiac
events. However, unlike in typical models for multi-
ple recurrent events, we made no assumption that the
hazard ratios were identical to those for the ﬁrst
cardiac event. The endpoint was deﬁned as the next
occurrence of a cardiac event of any type (syncope,
aborted cardiac arrest, sudden cardiac death).
Likelihood ratio tests were used to compare nested
Cox-models, after using the grouped jackknife co-
variance estimator to verify that there was no need
to account for potential dependencies as a result of
family membership in inherited LQTS. All statistical
tests were 2-sided 0.05 level tests. Analyses were
carried out with SAS software (version 9.3, SAS
Institute, Cary, North Carolina).
RESULTS
BASELINE CLINICAL CHARACTERISTICS. We stud-
ied 1,530 patients with LQTS who were started on 1
of 4 different b-blockers. More patients were started
heart
TABLE 1 Clinical Characteristics of Patients With LQTS According to
First b-Blocker Therapy*
Atenolol
(n ¼ 441)
Metoprolol
(n ¼ 151)
Propranolol
(n ¼ 679)
Nadolol
(n ¼ 259) p Value†
Demographics
Age at ﬁrst b-blocker, yrs 16  10 24  10 11  11 18  11 <0.001
Female sex: number, % 254 (58) 105 (70) 412 (61) 149 (58) 0.06
Calendar year of ﬁrst b-blocker 1,998  6 1,999  6 1,993  9 1,997  8 <0.001
History
Syncope or aborted cardiac
arrest before ﬁrst b-blocker
188 (43) 85 (56) 334 (49) 130 (50) 0.02
Family history of LQTS 76 (17) 20 (13) 148 (22) 52 (20) 0.06
ECG
QTc-interval value, ms‡ 492  49 496  52 500  58 490  51 0.13
RR interval value, ms‡ 803  218 842  212 753  247 863  231 <0.001
Therapy before b-blocker
Pacemaker before ﬁrst b-blocker 15 (3) 5 (3) 31 (5) 8 (3) 0.64
Initial b-blocker doses
Adults age 18 yrs old or older,
mg/day
49  29 70  49 117  105 54  46 NA
Children younger than age 18 yrs,
mg/day
40  27 53  47 52  54 38  30 NA
Adults age 18 yrs old or older,
mg/kg/day§
0.7  0.3 1.2  0.9 2.1  2.3 1  0.8 NA
Children younger than age 18 years,
mg/kg/dayk
1.0  0.7 1.4  1.0 2.3  1.5 1.0  0.8 NA
*Values are mean  SD or n (%). †The p values are based on the Kruskal-Wallis test and refer to the signiﬁcance
of the difference across the 4 b-blocker groups. ‡First recorded QTc and RR values (baseline) in LQTS Registry.
§Number of patients aged 18 years or older whose dose and weight at the initiation of b-blocker therapy were
available (n ¼ 157). kNumber of patients younger than 18 years of age whose dose and weight at the initiation of
b-blocker therapy were available (n ¼ 379).
ECG ¼ electrocardiogram; LQTS ¼ long QT syndrome; NA ¼ p values not applicable.
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nadolol (17%), and metoprolol (10%). Baseline char-
acteristics, compared by type of ﬁrst b-blocker initi-
ated, are shown in Table 1. Initial b-blocker doses
calculated for patients started at 18 years of age or
older and for those started before 18 years of age are
also shown. Propranolol was started at a younger age
and at an earlier calendar year than the other
b-blockers, nadolol was associated with the slowest
baseline heart rate, and approximately 50% of the
patients experienced a cardiac event before the start
of b-blockers.
MULTIVARIATE TIME-DEPENDENT ANALYSES: FIRST
CARDIAC EVENTS IN THE GENERAL POPULATION.
Cardiac events for each time-dependent b-blocker
and results from the covariate-adjusted Cox models
are shown in Table 2. Hazard ratios are reported
relative to discontinuing b-blockers after therapy
initiation. In the overall LQTS population, there was
insufﬁcient evidence of differences among the 4 b-
blockers in preventing either ﬁrst cardiac events or
the more serious cardiac events in the study popula-
tion (3-df likelihood ratio test p ¼ 0.19 and p ¼ 0.16,
respectively).MULTIVARIATE TIME-DEPENDENT ANALYSES: FIRST
CARDIAC EVENTS IN LQT1 AND LQT2. In LQT1, the
risk reduction for any b-blocker was 57% (p < 0.01),
with insufﬁcient evidence of differential efﬁcacy
by drug (likelihood ratio test p ¼ 0.83) (Table 3). All
4 b-blockers were similarly protective, and risk
reduction efﬁcacy ranged from 50% to 62%. In
LQT2, there was signiﬁcant variability in efﬁcacy
by drug (likelihood ratio test p ¼ 0.04), with
nadolol being the only b-blocker showing a signiﬁ-
cant reduction in the risk of cardiac events (hazard
ratio 0.40, p < 0.05). The interaction of genotype
with b-blockers in the combined LQT1 and LQT2
model (n ¼ 785) suggested insufﬁcient statistical
evidence (likelihood ratio test p ¼ 0.14) (data not
shown).
UNIVARIATE ANALYSES: RECURRENT CARDIAC
EVENTS. Recurrent cardiac events occurred less
frequently in patients initially prescribed metoprolol,
nadolol, and atenolol compared with propranolol
(p ¼ 0.002) (Central Illustration), with the 2-year
cumulative probabilities of cardiac events being
27%, 31%, 33%, and 48%, respectively. The 5-year
cumulative probability of cardiac events ranged
from 33% to 61%.
MULTIVARIATE TIME-DEPENDENT ANALYSES:
RECURRENT CARDIAC EVENTS. The hazard ratios
for subsequent cardiac events among patients who
had a ﬁrst cardiac event while taking b-blocker ther-
apy (n ¼ 315) indicate that b-blockers are not equiv-
alent (3-df likelihood ratio test p ¼ 0.004) (Table 4).
Risk reduction in recurrent cardiac events for meto-
prolol, nadolol, and atenolol compared with pro-
pranolol were 59% (p ¼ 0.04), 48% (p < 0.01), and
43% (p < 0.01), respectively.
DISCUSSION
This study compares the efﬁcacy of various
b-blockers in a large LQTS population with long-term
follow-up. In previous studies, we showed that
b-blockers are effective in reducing the overall risk of
cardiac events in both adults (9) and children (10),
and b-blockers are considered ﬁrst-line therapy for
patients with LQTS (11). Controversy exists regarding
the most effective b-blocker, and earlier small studies
suggested nonuniform effects for different drugs
(12). Our study indicates that although different
b-blockers are similarly effective in preventing ﬁrst
cardiac events in the general LQTS population,
further attention should be given to some agents over
the others, particularly in speciﬁc LQTS genotypes
and in reduction of recurrent events.
TABLE 2 Drug-Speciﬁc Cardiac Event Rates on b-Blocker Therapy and Covariate-Adjusted Hazard Ratios Relative to Discontinuing b-Blockers*
Time-Dependent Variable
First Cardiac
Events†
Hazard Ratio‡
(95% CI) p Value
Aborted Cardiac
Arrest/Sudden
Cardiac Death†
Hazard Ratio‡
(95% CI) p Value
Atenolol 100/414 (24.2) 0.71 (0.50–1.01) 0.06 18/418 (4.3) 0.38 (0.20–0.74) 0.004
Metoprolol 25/147 (17.0) 0.70 (0.43–1.15) 0.16 1/147 (0.7) 0.08 (0.01–0.62) 0.02
Propranolol 160/395 (40.5) 0.65 (0.46–0.90) 0.01 42/352 (11.9) 0.42 (0.24–0.74) 0.002
Nadolol 61/363 (16.8) 0.51 (0.35–0.74) <0.001 12/386 (3.1) 0.29 (0.14–0.61) <0.001
Any b-blocker (pool of all 4 groups) 346/1,319 (26.2) 0.63 (0.47–0.86) 0.004 73/1,303 (5.6) 0.37 (0.22–0.61) <0.001
Test of equality of 4 drug-speciﬁc
hazard ratios§
0.19 0.16
Values are n/N (%), unless otherwise noted. *Numbers of patients who discontinued b-blocker therapy at the end of follow-up were 211 for ﬁrst cardiac events analysis (total events ¼ 49,
23.2%) and 227 for aborted cardiac arrest/sudden death (total events ¼ 20, 8.8%). Total ﬁrst cardiac events ¼ 395, of which aborted cardiac arrest ¼ 25 and death ¼ 31. †Number of patients
in each group at the end of follow-up (n). These are different from baseline counts because the analyses were time dependent, allowing patients to switch and go on and off drugs during
follow-up. ‡Adjusted hazard ratios: see the methods section for covariates included in the Cox models when computing hazard ratios. §There was insufﬁcient evidence of differential effects by
type of b-blocker for ﬁrst cardiac event or aborted cardiac arrest/sudden cardiac death (3-df likelihood ratio test p ¼ 0.19 and p ¼ 0.16, respectively).
CI ¼ conﬁdence interval.
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clinically or genetically diagnosed with LQTS, and
the 4 b-blockers showed similar risk reduction when
compared with not receiving b-blocker therapy. The
age when ﬁrst b-blocker therapy was prescribed was
signiﬁcantly different among the 4 drugs, with pro-
pranolol, the ﬁrst b-blocker on the market, started at a
younger age compared with the other b-blockers. It is
known from previous studies that younger patients
with LQTS are at higher risk for cardiac events
compared with patients who are older (10,13).
Therefore, adjustments for age and calendar year
when b-blocker therapies were initiated were carried
out in this study to correct for these confounding
factors. Further adjustment for LQTS severity wasTABLE 3 Genotype- and Drug-Speciﬁc First Cardiac Event* Rates on b
Relative to Discontinuing b-Blockers† in Patients With LQT1 and LQT2
Time-Dependent Variable
LQT1
(n ¼ 379)
(Total CE ¼ 87)
First CE‡
Hazard Ratio
(95% CI)
Atenolol 21/105 (20.0%) 0.43 (0.22–0.8
Metoprolol 3/20 (15.0%) 0.44 (0.13–1.54
Propranolol 26/72 (36.1%) 0.38 (0.19-0.7
Nadolol 22/125 (17.6%) 0.50 (0.25–0.9
Test of equality of 4 drug-speciﬁc
hazard ratiosk¶
Values are n/N (%), unless otherwise noted. *CE denotes cardiac events (syncope or abo
death ¼ 4, total ﬁrst CE in LQT2 ¼ 85; of which ACA ¼ 6 and death ¼ 2. †Numbers of p
(total events ¼ 15, 26.3%) and 37 for LQT2 (total events ¼ 9, 24.3%). ‡Number of patien
analyses were time dependent, allowing patients to switch and go on and off drugs durin
in the Cox models when computing hazard ratios. kIn patients with LQT2, there was sig
patients with LQT1, there was insufﬁcient evidence (3-df LRT p ¼ 0.83). ¶Test of equality
(n ¼ 785) suggested insufﬁcient statistical evidence (4-df LRT p¼ 0.14) (data not show
CE ¼ cardiac event; CI ¼ conﬁdence interval; LQT1 ¼ long QT syndrome genotype 1;achieved by including other relevant covariates in the
multivariate Cox-model as described earlier.
In genotype-speciﬁc analysis, all b-blockers were
similarly effective in reducing the risk for cardiac
events in LQT1 but not in LQT2, despite the statis-
tically insufﬁcient evidence of differential efﬁcacy of
b-blockers by genotype. However, because the re-
sults are close to the 0.1 p value for signiﬁcance level
and there is clinical plausibility to the differences,
we report the analyses of the individual genotypes
separately. Analysis of b-blockers in LQT2 showed
that nadolol provided the only signiﬁcant risk
reduction when compared with other b-blockers.
One explanation for differences observed by geno-
type can be related to triggers that initiate cardiac-Blocker Therapy and Covariate-Adjusted Hazard Ratios
LQT2
(n ¼ 406)
(Total CE ¼ 85)
§
p Value First CE‡
Hazard Ratio§
(95% CI) p Value
6) 0.02 28/114 (24.6%) 1.04 (0.48–2.27) 0.92
) 0.2 10/46 (21.7%) 0.82 (0.32–2.09) 0.67
3) 0.004 28/100 (28.0%) 0.65 (0.29–1.42) 0.28
8) 0.04 10/109 (9.2%) 0.40 (0.16–0.98) 0.04
0.83 0.04
rted cardiac arrest [ACA] or death), total ﬁrst CE in LQT1 ¼ 87; of which ACA ¼ 3 and
atients who discontinued b-blocker therapy at the end of follow-up were 57 for LQT1
ts at end of follow-up. These numbers are different from baseline counts because the
g follow-up. §Adjusted hazard ratios: see the methods section for covariates included
niﬁcant evidence of differential effects by type of b-blocker (3-df LRT p ¼ 0.04); in
for the interaction of genotype with b-blockers in the combined LQT1 þ LQT2 model
n).
LQT2 ¼ long QT syndrome genotype 2; LRT ¼ likelihood ratio test.
CENTRAL ILLUSTRATION Cumulative Probability of a Subsequent Cardiac Event
Among Patients With 1 Cardiac Event While Taking b-Blocker Therapy
Kaplan-Meier estimates of the cumulative probability of a subsequent cardiac event
following 1 cardiac event while taking b-blocker therapy, stratiﬁed by type of b-blocker:
atenolol, metoprolol, nadolol, or propranolol. The p value was based on the 4-group
log-rank test, unadjusted for covariates or time-dependent changes to b-blocker status.
The numbers of subjects at risk are given yearly, up to 5 years, for a ﬁrst recurrent cardiac
event while taking b-blockers.
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1356events within each genotype. In LQT1, patients
are more likely to have cardiac events during exer-
cise, when b-adrenergic activity is meaningfully
augmented (14). Any b-blocker that can achieve
b-adrenergic blockade is likely to be effective. In fact
this is observed in nadolol, which showed nearly a
similar risk reduction (hazard ratio) in both LQT1
and LQT2, as a result of its b-adrenergic blocking
activity.
In contrast, patients with LQT2 are less likely to
experience cardiac events during exercise because
their events are triggered by auditory stimulation or
sudden startle (15), activities mediated by both neu-
rotransmitters and catecholamines. It could be that
nadolol, a hydrophilic long-acting noncardioselective
b-blocker with the longest elimination half-life, of-
fers the most stable, lasting degree of b-blockade.
Other pharmacodynamic properties, such as a lack
of both intrinsic sympathomimetic activity and
membrane-stabilizing activity, may also play roles in
this beneﬁcial effect observed in LQT2. More studies
are necessary to investigate the mechanism behind
this observation.
In the recurrent cardiac events analysis, we com-
pared the efﬁcacy of b-blockers in patients who had aprior cardiac event while taking b-blockers. Our re-
sults suggested that b-blockers are not all alike in
preventing recurrent events, and propranolol seemed
to be the least effective of the 4 b-blockers. Clinically,
patients who continue to have cardiac events despite
taking b-blocker therapy are considered to be a very
high-risk group (11,16). This novel observation for
propranolol could reﬂect its different role in this
high-risk LQTS population. Kawakami et al. (17)
studied the effect of b-blockers on the wild-type
hERG channel, and the rapid component of the
cardiac potassium channel (IKr) was blocked by
high concentrations of propranolol. This effect was
not seen with atenolol or metoprolol within the
therapeutic concentration range. It may be that high-
risk patients with LQTS who have recurrent events
while taking b-blockers are more sensitive to pro-
pranolol’s undesirable hERG-blocking action, which
may explain why, given the drug’s other useful
properties such as its antiadrenergic and INa blocking
effects (18,19), propranolol is not as effective in these
patients as expected. Clinical experience suggests
that patients who experience cardiac events while
taking b-blockers are at augmented risk for sudden
cardiac death, and such patients may beneﬁt from
nonpharmacological antiadrenergic therapies such as
left cervicothoracic sympathetic denervation or an
ICD (11,20,21).
Our ﬁndings differ from those from a recent
study reported by Chockalingam et al. (5). In their
study, the analysis of cardiac events in previously
asymptomatic patients (n ¼ 281) showed no differ-
ences in cardiac event occurrence among metopro-
lol, propranolol, and nadolol. Although there was a
signiﬁcant age difference when b-blockers were
started (p < 0.001) in the overall population (5), but
not in the subset of previously symptomatic
patients (p ¼ 0.8), no adjustment for this age dif-
ference was performed. In contrast to our study, in
which we found 25 cardiac events (17%) and only 1
serious event (0.7%) in patients with LQTS who
started on metoprolol, the study by Chockalingam
et al. study found a higher rate (29%) of cardiac
events among symptomatic patients receiving
metoprolol compared with those taking propranolol
and nadolol (5). Our study included a 4-fold
larger number of patients with LQTS overall
(1,530 compared with 382) and of patients taking
metoprolol (147 compared with 35). Our observation
indicates fewer cardiac events for patients with
LQTS who were receiving metoprolol therapy (17%),
after adjusting for the history of prior cardiac
events (symptomatic patients) in the Cox model. In
addition, our time-dependent analyses took into
TABLE 4 Drug-Speciﬁc Recurrent Cardiac Event Rates* and Covariate-Adjusted Hazard
Ratios Relative to Propranolol† Among Patients With 1 Prior Cardiac Event on b-Blockers
Time-Dependent
Variable
Number of
Patients at End
of Follow-Up‡
Recurrent
Cardiac Events§
Hazard Ratiok
(95% CI) p Value
Atenolol: propranolol 87 33 (37.9) 0.57 (0.38–0.87) 0.009
Metoprolol: propranolol 23 6 (26.1) 0.41 (0.17–0.98) 0.04
Nadolol: propranolol 65 22 (33.9) 0.52 (0.32–0.84) 0.008
No b-blockers
(off therapy during follow-up)
25 10 (40.0) 0.91 (0.46–1.80) 0.77
Test of equality of 4 drug-speciﬁc hazard ratios¶ 0.004
Values are n (%), unless otherwise noted. *The time origin for this analysis was the date of the ﬁrst cardiac event
while taking b-blockers. †Number of patients who were on propranolol at the end of follow-up was 115 (recurrent
events ¼ 83, 72.2%). ‡Number of patients at end of follow-up who already had 1 prior ﬁrst cardiac event on
b-blockers. §Cardiac events include syncope, aborted cardiac arrest (ACA), or death at the end of follow-up. Total
recurrent cardiac events ¼ 154, of which ACA ¼ 8 and death ¼ 7. kAdjusted hazard ratios: see the methods
section for covariates included in the Cox models when computing hazard ratios. ¶There was evidence of dif-
ferential effects by type of b-blocker for recurrent events (3-df likelihood ratio test p ¼ 0.004) when comparing
hazard ratios for atenolol, metoprolol, nadolol, and propranolol, with propranolol as the least effective.
CI ¼ conﬁdence interval.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Beta-blockers
differ in selectivity for adrenergic receptor subtypes, adverse
effects, and dosing, and these may inﬂuence efﬁcacy and
tolerability in patients with genetic subtypes of the LQTS.
TRANSLATIONAL OUTLOOK: Further studies are needed to
guide genotype-speciﬁc selection of optimum b-blockers agents
for use in selected subpopulations of patients with LQTSs.
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patients receiving various b-blocker therapies with
adjustment for relevant covariates, as described
earlier, several factors that should contribute to
more accurate analysis of risk/beneﬁt consider-
ations. It is interesting that Chockalingam et al. (5)
found that propranolol shortened the QTc, but this
has not generally been our experience
with b-blockers (11). We previously showed that
nadolol was signiﬁcantly effective in reducing the
risk for cardiac events in LQT2, but propranolol was
not (22).
We excluded patients treated with ICDs in our
analysis so we could focus exclusively on b-blocker
therapy as a pharmacological therapy, as described
in the methods section. When patients with ICDs
inserted before or during b-blocker therapy were
included in the analyses, the results were essentially
the same.
STUDY LIMITATIONS. Similar to other studies using
data from registries, there are limitations inherent in
this type of observational study. Lack of randomiza-
tion is the most important concern. Randomization of
therapy and long-term follow-up of patients with a
rare disease (e.g., LQTS) and infrequent events are
nearly impossible to do within a reasonable time
frame. This observational study adjusted for impor-
tant confounding factors by using appropriate statis-
tical analyses. We believe that our adjustments for
age and year when b-blockers were initiated are
important for reducing potential bias in this study.
Patients’ compliance in taking their medications is
another issue (23). This Registry study contains reli-
able data on the starting and stopping of b-blockers
in the time-dependent analyses, and we believe
such information provides reasonably reliable infor-
mation about patients’ compliance with b-blocker
therapy. In addition, we believe that whatever un-
measured noncompliance exists would likely be
similar among patients taking the various b-blockers.
Therefore, noncompliance, if present, should not
differentially affect the adjusted hazard ratios
reported in the analysis.
Although we do not have consistent information
of b-blocker dosage by weight over time for all
patients (on and off), we calculated the doses for
both adults and younger patients in milligrams per
day and also in milligrams per kilogram for those
for whom weight was available at the initiation
of their known dose of b-blocker therapy, as
shown in Table 1. Both quantiﬁcations of b-blocker
therapy doses appear reasonable and within the
accepted and recommended dosing for this therapy
in LQTS.CONCLUSIONS
In conclusion, the 4 major b-blockers seem to be
equally effective in reducing the risk of ﬁrst cardiac
events in LQTS. Our ﬁndings highlight the somewhat
augmented therapeutic beneﬁt of nadolol, and we
believe it is the preferred b-blocker in the general
management of patients with LQTS, with slightly
better effect in patients with LQT2 compared with
other b-blockers. Patients experiencing cardiac events
while receiving b-blocker therapy are at high risk for
subsequent life-threatening cardiac events, and our
ﬁndings indicate that propranolol is the least effective
agent in preventing recurrent cardiac events in
these high-risk patients.
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